By: IPP Bureau
Last updated : August 01, 2025 2:47 pm
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Jubilant Ingrevia Limited has reported 54 per cent jump in its net profit at Rs. 75 crore in Q1 FY26 as compared to Rs. 49 crore during Q1 FY25. Total revenue in Q1 FY26 stood at Rs. 1,038 crore as compared to Rs. 1,024 crore, reflecting a YoY growth of 1 per cent. Total EBITDA was Rs. 153 crore with a growth of 29 per cent as compared to Rs. 119 crore in Q1 FY25.
Commenting on the Company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said: “We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally with QoQ growth. Ongoing cost optimisation initiatives have further enhanced profitability, with EBITDA for the quarter rising by 29% YoY and Profit After Tax increasing by an impressive 54% YoY.
“The global chemicals sector is emerging from the inventory destocking phase. Specialty chemicals are seeing volume growth, though pricing remains stable. Commodity segments continue to face demand challenges, with prices stabilising at lower levels. China +1 macro-trend is creating more opportunities for us, especially in our specialty chemicals segment where we are witnessing healthy funnel across sub-segments.
“The Pharmaceutical end-use market continues to show steady growth, driven by stable pricing and consistent volumes growth across various derivatives as well as Intermediates segments.
“The Agrochemical sector continues its upward momentum, driven by strong volume growth both on YoY and QoQ basis. Average prices have been stable for last few quarters now.
“The Nutrition market saw stable volumes during the quarter. Niacinamide demand remained muted as customers delayed purchases amid competitive offerings, while choline demand rose notably, with prices holding steady.
For FY26, we anticipate continued growth and improved performance, driven by advancements in our Specialty Chemicals and Nutrition businesses, and expected recovery in Acetyls portfolio. Alongside we remain committed towards our Lean 2.0 cost efficiency initiatives. We are on track to deliver the big CDMO order in early 2026, which should further accelerate our growth trajectory in coming quarters.”
Commenting on the company’s performance, Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said: ““The financial results for Q1FY26 are in line with our Pinnacle strategy which is reflected in the continued growth momentum, driven by the Specialty & Nutrition segment. In our CDMO business, the pharmaceutical segment saw a significant expansion in its opportunity pipeline, with the funnel doubling in size in last few months. This growth was driven by strong traction from innovative pharmaceutical companies and Tier-1 CDMOs across key global markets including the EU, US, and Japan. With above progress, we are confident that our topline and margins will continue to show the expected growth trajectory in coming quarters”